ClinicalTrials.gg
CompletedNCT00074529Updated Jul 24, 2015

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

A Phase 2 interventional study of MK0677 in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Enrollment
3rd of 29
512 · median 34
Started
2003
the only one that year
Phase 2
8 of 31
1 open now
Registered
2nd of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 2, and was the 2nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Patients must have probable Alzheimer's disease of mild or moderate severity.
  • A brain scan and laboratory results must be consistent with Alzheimer's disease.
  • The patient must be otherwise medically healthy.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Double (Participant, Investigator)
Enrollment
512 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Cognitive function over 12 month period; safety and tolerability

    Time frame: over 12 month period

Secondary outcomes

  1. AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.

    Time frame: over a 6 month and 12 month period

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7. PubMed 19015485 ↗
  • Sevigny JJ, Peng Y, Liu L, Lines CR. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial. Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):119-24. doi: 10.1177/1533317509350298. PubMed 19949163 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2003
First posted
Dec 16, 2003
Start
Oct 2003
Primary completionActual
Jan 2006
CompletionActual
Jan 2006
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00074529
Responsible party
Sponsor
First posted
Dec 16, 2003
Start date
Oct 2003
Primary completion
Jan 2006
Completion
Jan 2006
Last update
Jul 24, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion